Learn more about the announcement from Orphazyme, communicating the topline results from the Phase 2/3 trial of arimoclomol for...
The primary focus of Myositis Support and Understanding is muscle diseases which are referred to as “Idiopathic Inflammatory Myopathies” or “Acquired Myopathies,” meaning muscle diseases which are typically not inherited and are caused by the immune system attacking muscles, connective tissue, blood vessels, and/or the skin.
Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
Choose your language
- Explore Myositis
- Financial Assistance Program
- #ItsMyTurn: Becoming a Plasma Donor Hero
- Myositis Clinical Trials
- Myositis Empower Walk
- Myositis Webinars
- The Grieving Project
- Upcoming Events